Senseonics Holdings, Inc. (SENS), a medical technology company, priced the public offering of 8 million shares at a price of $5.00 per share and, in lieu of common stock, issued pre-funded warrants to certain investors to purchase 8 million shares at a purchase price of $4.999 per pre-funded warrant share.
The gross proceeds from the offering are expected to be $80 million.
Senseonics intends to use the net proceeds from the public offering to fund the ongoing launch of Eversense 365, its glucose monitoring product, and the continued development of its pipeline products, as well as for working capital and general corporate purposes.
In addition, Senseonics has granted the underwriters a 30-day option to purchase up to an additional 2.40 million shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 4, 2026, subject to closing conditions.
Senseonics is focused on the development, manufacturing, and commercialisation of glucose monitoring products. The firm's CGM systems include Eversense 365 and Eversense E3, which use small sensors fully implanted under the skin that communicate with a smart transmitter that automatically sends glucose data to the mobile app every 5 minutes.
SENS has traded between $5.25 and $15.20 over the last year. The stock closed Thursday's trade at $6.61, up 2.88%.
In the overnight market, SENS is up $5.50, down 16.79%.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.